Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/1/2026, 12:00:00 AM
European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. High importance due to major drug approval potential, expected.
Korean Translation
유럽연합 집행위원회로부터 백금 기반 화학요법 이후 질병이 진행된 성인 확장병기 소세포폐암(ES-SCLC) 환자 치료를 위한 임딜트라(타르라타맙)의 판매 허가를 승인받음. 신약 승인에 따른 매출 증대 기대감으로 높은 중요도로 분류함, 예상됨.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM